GLP-1 weight loss claims on TikTok: separating hype from evidence

What did @ladanah72 actually say?

Honestly, it's not entirely clear. The transcript reads like a fragment of a song, a skit, or a heavily slang-laden conversation. The phrase "doing her zenp" appears to reference semaglutide (Ozempic/Wegovy), which has picked up street-level nicknames across social media. The rest of the transcript, "trying to be a no-woman," "you need a dick," "you need a move son," reads more like interpersonal commentary than any kind of health claim. There is no dosing advice, no weight loss promise, and no medical instruction here. What we have is a GLP-1 drug name dropped into what sounds like a culture or lifestyle moment, not a health tutorial.

The creator appears to be using "zenp" as a casual reference to semaglutide use, possibly implying a character in the video is on the medication. That's the extent of the medical content.

Does the science back this up?

There is nothing to fact-check scientifically here because no medical claims were made. The reference to semaglutide as a social identifier, something a person is "doing," does reflect a real cultural shift. GLP-1 receptor agonists have become status-adjacent in certain social circles, which is itself worth noting.

Semaglutide does have robust clinical backing. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) found that once-weekly subcutaneous semaglutide 2.4 mg produced an average 14.9% body weight reduction over 68 weeks in adults with obesity. Tirzepatide's SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed up to 22.5% weight loss at the highest dose. These are real, peer-reviewed findings. But none of that science is what this video is communicating.

The cultural framing of GLP-1 use as something people "do" casually, like a lifestyle accessory, runs ahead of what the clinical evidence supports. These are prescription medications with side effect profiles, contraindications, and monitoring requirements.

What did they get wrong (or right)?

The creator did not get anything medically wrong because they did not say anything medically substantive. That is almost the problem. Videos like this one normalize GLP-1 drugs as casual cultural currency without any acknowledgment that semaglutide carries real risks: nausea, vomiting, gastroparesis, pancreatitis risk, and contraindications in patients with a personal or family history of medullary thyroid carcinoma (FDA label, 2021).

There is also a growing body of concern about how social media trivializes these medications. A 2023 commentary in The Lancet Diabetes and Endocrinology (Tahrani and Morton) flagged the risk of off-label and unsupervised use driven partly by viral social content. When a drug becomes a meme or a nickname, the medical gatekeeping tends to erode.

The creator is not doing anything predatory here. But they are contributing, probably unintentionally, to a media environment where GLP-1 drugs feel as casual as a vitamin recommendation.

What should you actually know?

If you landed here because someone on TikTok referenced "zenp" or a similar nickname and you are now curious about semaglutide, here is the short version of what the evidence actually says.

• Semaglutide (Wegovy for obesity, Ozempic for type 2 diabetes) is a GLP-1 receptor agonist approved by the FDA. It works by mimicking a gut hormone that reduces appetite and slows gastric emptying.
• It requires a prescription and medical oversight. It is not a casual supplement.
• Common side effects include nausea, diarrhea, vomiting, and constipation, especially during dose escalation (Davies et al., 2021, Diabetes Care).
• Compounded versions of semaglutide are not equivalent to FDA-approved brand-name drugs. The FDA has explicitly warned consumers about compounded semaglutide products (FDA Safety Communication, 2023).
• Weight regain after stopping the medication is common. The STEP 4 extension trial (Rubino et al., 2021, JAMA) found that participants regained about two-thirds of lost weight within a year of discontinuation.

Social media can be a starting point for curiosity, but it is a poor substitute for a clinical conversation. If you are considering a GLP-1 medication, talk to a licensed provider who can review your health history, not a TikTok comment section.